|Title||Combined p21-activated kinase and farnesyltransferase inhibitor treatment exhibits enhanced anti-proliferative activity on melanoma, colon and lung cancer cell lines.|
|Authors||Giampiero Porcu, Ainslie B Parsons, Daniele Di Giandomenico, Giuseppe Lucisano, Maria Giovanna Mosca, Charles Boone, Antonella Ragnini-Wilson|
|Abstract||Farnesyltransferase inhibitors (FTIs) are anticancer agents with a spectrum of activity in Ras-dependent and independent tumor cellular and xenograph models. How inhibition of protein farnesylation by FTIs results in reduced cancer cell proliferation is poorly understood due to the multiplicity of potential FTase targets. The low toxicity and oral availability of FTIs led to their introduction into clinical trials for the treatment of breast cancer, hematopoietic malignancy, advanced solid tumor and pancreatic cancer treatment, and Hutchinson-Gilford Progeria Syndrome. Although their efficacy in combinatorial therapies with conventional anticancer treatment for myeloid malignancy and solid tumors is promising, the overall results of clinical tests are far below expectations. Further exploitation of FTIs in the clinic will strongly rely on understanding how these drugs affect global cellular activity.|
|Citation||Mol. Cancer 2013; 12:88|
YeastPhenome.org is running in beta version. The data are available for download, but, as of today, we cannot guarantee lack of errors or code bugs introduced during processing. This warning will be removed after all cross-checks and validations have been completed. In the meantime, please, be careful when using the data.